IC14 IS THE ONLY CLINICAL-STAGE ANTIBODY PLATFORM DRUG THAT MODULATES CD14, A MASTER REGULATOR OF THE IMMUNE RESPONSE

Opening a door to immunotherapy for a wide range of diseases in pulmonology, neurology, cardiology, orthopedics and transplant.

abr1

$4.5 Bn/year Global Market

Acute indication

$11 Bn COST TO US HOSPITALS

1 MILLION PATIENTS AT RISK

ZERO APPROVED DRUGS

Phase 2 (2017)

Exciting pilot clinical data

FDA IND open

Grant application filed

Strong collaborations

PERSONALISED with matching diagnostic

shutterstock_528563770_3D_illustration_human_body_brain cropped(2)

$1.1 Bn/year Global Market

Chronic indication

$6 Bn COSTS

ZERO EFFECTIVE DRUGS

Phase 1b (2017)

Strong collaborations

Grant application filed

PERSONALISED with matching diagnostic

shutterstock_62822560_human_body_heart_beat_monitoring_rate edit

$2.9 Bn/ Global Market

Acute indication

20% MORTALITY

$6 Bn COSTS

ZERO EFFECTIVE DRUGS

Pre-clinical (2017)

PERSONALISED with matching diagnostic

Providing opportunities for a strong return for investors
who take pride in making a global impact

Contact us to find out more about our programs
CONTACT

Our Team

Implicit Bioscience is founded upon the principle that quality people drive success and create value

BOARD

MANAGEMENT

ADVISORY

LOGO_FOOTER

Contact us to find out more about our programs

CONTACT